nach oben

Erschienen in:

09.08.2016 | Original Paper

Global or Granulosa Cell-Specific Pten Mutations in Combination with Elevated FSH Levels Fail to Cause Ovarian Tumours in Mice

verfasst von: Dannielle H. Upton, Kirsty A. Walters, Rachel E. Allavena, Mark Jimenez, Reena Desai, David J. Handelsman, Charles M. Allan

Erschienen in: Discover Oncology | Ausgabe 5-6/2016

Einloggen, um Zugang zu erhalten

Abstract

Phosphatase and tensin homologue (PTEN) is a known tumour suppressor. To explore the role of Pten in ovarian tumorigenesis, we used transgenic (Tg) SOX2. Cre and AMH. Cre mouse models to direct global Pten haploinsufficiency (Pten ^+/−) or ovary-specific granulosa cell (GC) Pten disruption (Pten ^GC). Pten mutant models were combined with progressively rising Tg-follicle-stimulating hormone (TgFSH) levels to study the tumorigenic potential of combined genetic/endocrine modification in vivo. Global Pten ^+/− mice exhibited grossly detectable tumours in multiple organs including uterine and mammary tissue and displayed reduced survival. Despite extra-ovarian tumorigenesis, Pten ^+/− females had no detectable ovarian tumours, although elevated corpus luteum numbers increased ovary size and estrous cycling was altered. Combined TgFSH/Pten ^+/−mice also had no ovarian tumours, but early survival was reduced in the presence of TgFSH. Ovary-specific Pten ^GC ± TgFSH females exhibited no detectable ovarian or uterine tumours, and corpus luteum numbers and estrous cycling remained unchanged. The non-tumorigenic ovarian phenotypes in Pten ^+/− and Pten ^GC ± TgFSH mice support the proposal that multi-hit genetic mutations (including ovarian and extra-ovarian tissue) initiate ovarian tumours. Our findings suggest that elevated FSH may reduce early cancer survival; however, the ovary remains remarkably resistant to Pten-induced tumorigenic changes even in the presence of uterine and reproductive cancers.

Obata K et al. (1998) Frequent PTEN/MMAC mutations in Endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58(10):2095–2097PubMed

Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci 96(8):4240–4245CrossRefPubMedPubMedCentral

Suzuki A et al. (1998) High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 8(21):1169–1178CrossRefPubMed

Stambolic V et al. (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95(1):29–39CrossRefPubMed

Sansal I, Sellers WR (2004) The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22(14):2954–2963CrossRefPubMed

Lee JH et al. (1989) Allele loss at the c-Ha-ras1 locus in human ovarian cancer. Cancer Res 49(5):1220–1222PubMed

Ehlen T, Dubeau L (1990) Loss of heterozygosity on chromosomal segments 3p, 6q and 11p in human ovarian carcinomas. Oncogene 5(2):219–223PubMed

Lee JH et al. (1990) Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas. Cancer Res 50(9):2724–2728PubMed

Russell S et al. (1990) Allele loss from chromosome 17 in ovarian cancer. Oncogene 5(10):1581–1583PubMed

10.

Eccles D et al. (1990) Allele losses on chromosome 17 in human epithelial ovarian carcinoma. Oncogene 5(10):1599–1601PubMed

11.

Carroll RS et al. (1991) In vivo regulation of FSH synthesis by inhibin and activin. Endocrinology 129(6):3299–3304CrossRefPubMed

12.

Zheng W et al. (1996) Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube. Am J Pathol 148(1):47PubMedPubMedCentral

13.

Chun SY et al. (1996) Hormonal regulation of apoptosis in early antral follicles: follicle-stimulating hormone as a major survival factor. Endocrinology 137(4):1447–1456PubMed

14.

Monniaux D, Pisselet C (1992) Control of proliferation and differentiation of ovine granulosa cells by insulin-like growth factor-I and follicle-stimulating hormone in vitro. Biol Reprod 46(1):109–119CrossRefPubMed

15.

Rao MC, Midgley AR, Richards JS (1978) Hormonal regulation of ovarian cellular proliferation. Cell 14(1):71–78CrossRefPubMed

16.

Richards J et al. (1994) Ovarian cell differentiation: a cascade of multiple hormones, cellular signals, and regulated genes. Recent Prog Horm Res 50:223–254

17.

UI M et al. (1989) An insulin-like growth factor-binding protein in ovarian follicular fluid blocks follicle-stimulating hormone-stimulated steroid production by ovarian granulosa cells*. Endocrinology 125(2):912–916CrossRefPubMed

18.

Broekmans FJ, Soules MR, Fauser BC (2009) Ovarian aging: mechanisms and clinical consequences. Endocr Rev 30(5):465–493CrossRefPubMed

19.

McTavish KJ et al. (2007) Rising follicle-stimulating hormone levels with age accelerate female reproductive failure. Endocrinology 148(9):4432–4439CrossRefPubMed

20.

Fathalla MF (1971) Incessant ovulation? A factor in ovarian neoplasia? Lancet 298(7716):163CrossRef

21.

Cramer D, Welch WR (1983) Determinants of ovarian cancer rsik II. Inferences regarding pathogenesis. J Natl Cancer Inst 71:717–721PubMed

22.

Hunzicker-Dunn M, Maizels ET (2006) FSH signaling pathways in immature granulosa cells that regulate target gene expression: branching out from protein kinase a. Cell Signal 18(9):1351–1359CrossRefPubMedPubMedCentral

23.

Hunzicker-Dunn ME et al. (2012) PKA and GAB2 play central roles in the FSH signaling pathway to PI3K and AKT in ovarian granulosa cells. Proc Natl Acad Sci U S A 109(44):8CrossRef

24.

Rodriguez-Viciana P et al. (1996) Activation of phosphoinositide 3-kinase by interaction with ras and by point mutation. EMBO J 15(10):2442PubMedPubMedCentral

25.

Gupta S et al. (2007) Binding of ras to phosphoinositide 3-kinase p110α is required for ras-driven tumorigenesis in mice. Cell 129(5):957–968CrossRefPubMed

26.

Podsypanina K et al. (1999) Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci 96(4):1563–1568CrossRefPubMedPubMedCentral

27.

Lague M-N et al. (2008) Synergistic effects of Pten loss and WNT/CTNNB1 signaling pathway activation in ovarian granulosa cell tumor development and progression. Carcinogenesis 29(11):2062–2072CrossRefPubMedPubMedCentral

28.

Fan H-Y et al. (2008) Targeted disruption of Pten in ovarian granulosa cells enhances ovulation and extends the life span of luteal cells. Mol Endocrinol 22(9):2128–2140CrossRefPubMedPubMedCentral

29.

Fan H-Y et al. (2009) Cell type–specific targeted mutations of Kras and Pten document proliferation arrest in granulosa cells versus oncogenic insult to ovarian surface epithelial cells. Cancer Res 69(16):6463–6472CrossRefPubMedPubMedCentral

30.

Hayashi S et al. (2002) Efficient gene modulation in mouse epiblast using a Sox2Cre transgenic mouse strain. Mech Dev 119(Supplement(0)):S97–S101CrossRefPubMed

31.

Schwenk F, Baron U, Rajewsky K (1995) A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res 23(24):5080–5081CrossRefPubMedPubMedCentral

32.

Allan CM et al. (2010) Follicle-stimulating hormone increases bone mass in female mice. Proc Natl Acad Sci U S A 107(52):22629–22634CrossRefPubMedPubMedCentral

33.

Vignarajan S et al. (2014) Loss of PTEN stabilizes the lipid modifying enzyme cytosolic phospholipase a(2)alpha via AKT in prostate cancer cells. Oncotarget 5(15):6289–6299CrossRefPubMedPubMedCentral

34.

Lesche R et al. (2002) Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 32(2):148–149CrossRefPubMed

35.

Lim P et al. (2009) Sertoli cell androgen receptor DNA binding domain is essential for the completion of spermatogenesis. Endocrinology 150(10):4755–4765CrossRefPubMed

36.

Lécureuil C et al. (2002) Sertoli and granulosa cell-specific cre recombinase activity in transgenic mice. Genesis 33(3):114–118CrossRefPubMed

37.

Walters KA et al. (2012) Targeted loss of androgen receptor signaling in murine granulosa cells of Preantral and antral follicles causes female subfertility. Biol Reprod 87(6):151 1-11CrossRefPubMed

38.

Allan CM et al. (2001) A novel transgenic model to characterize the specific effects of follicle-stimulating hormone on gonadal physiology in the absence of luteinizing hormone actions. Endocrinology 142(6):2213–2220PubMed

39.

Singh J, O’Neill C, Handelsman DJ (1995) Induction of spermatogenesis by androgens in gonadotropin-deficient (hpg) mice. Endocrinology 136(12):5311–5321PubMed

40.

Byun, D.-S., et al. (2011) Intestinal epithelial-specific PTEN inactivation results in tumor formation. 301: G856-G864

41.

Jimenez M et al. (2005) Validation of an ultrasensitive and specific immunofluorometric assay for mouse follicle-stimulating hormone. Biol Reprod 72(1):78–85CrossRefPubMed

42.

Harwood DT, Handelsman DJ (2009) Development and validation of a sensitive liquid chromatography-tandem mass spectrometry assay to simultaneously measure androgens and estrogens in serum without derivatization. Clin Chim Acta 409(1):78–84CrossRefPubMed

43.

McNamara KM et al. (2010) Measurement of sex steroids in murine blood and reproductive tissues by liquid chromatography-tandem mass spectrometry. J Steroid Biochem Mol Biol 121(3–5):611–618CrossRefPubMed

44.

Dixon D et al. (1999) Proliferative lesions of the ovary, uterus, vagina, cervix and oviduct in rats. Guides for Toxicologic Pathology:1

45.

Rudmann D et al. (2012) Proliferative and nonproliferative lesions of the rat and mouse mammary, Zymbal’s, preputial, and clitoral glands. Toxicol Pathol 40(6 suppl):7S–39SCrossRefPubMed

46.

Upton DH et al. (2015) Granulosa cell-specific Brca1 loss alone or combined with Trp53 haploinsufficiency and transgenic FSH expression fails to induce ovarian tumors. Horm Cancer 6(4):142–152CrossRefPubMed

47.

Reddy P et al. (2008) Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool. Science 319(5863):611–613CrossRefPubMed

48.

Jagarlamudi K et al. (2009) Oocyte-specific deletion of Pten in mice reveals a stage-specific function of PTEN/PI3K signaling in oocytes in controlling follicular activation. PLoS One 4(7):0006186CrossRef

49.

Kumar TR et al. (1999) Transgenic models to study gonadotropin function: the role of follicle-stimulating hormone in gonadal growth and tumorigenesis. Mol Endocrinol 13(6):851–865CrossRefPubMed

50.

Garson K et al. (2012) Technical challenges and limitations of current mouse models of ovarian cancer. J Ovarian Res 5(1):39CrossRefPubMedPubMedCentral

51.

Liu Z et al. (2015) FOXO1/3 and PTEN depletion in granulosa cells promotes ovarian granulosa cell tumor development. Mol Endocrinol 29(7):1006–1024CrossRefPubMedPubMedCentral

52.

Perets R et al. (2013) Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 24(6):751–765CrossRefPubMedPubMedCentral

53.

Courtois-Cox S et al. (2006) A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10(6):459–472CrossRefPubMedPubMedCentral

Titel: Global or Granulosa Cell-Specific Pten Mutations in Combination with Elevated FSH Levels Fail to Cause Ovarian Tumours in Mice
verfasst von: Dannielle H. Upton
Kirsty A. Walters
Rachel E. Allavena
Mark Jimenez
Reena Desai
David J. Handelsman
Charles M. Allan
Publikationsdatum: 09.08.2016
Verlag: Springer US
Erschienen in: Discover Oncology / Ausgabe 5-6/2016
Print ISSN: 1868-8497
Elektronische ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-016-0272-3

Springer Medizin

Global or Granulosa Cell-Specific Pten Mutations in Combination with Elevated FSH Levels Fail to Cause Ovarian Tumours in Mice

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5-6/2016

Different Types of Urinary Steroid Profiling Obtained by High-Performance Liquid Chromatography and Gas Chromatography-Mass Spectrometry in Patients with Adrenocortical Carcinoma

Prostate Cancer in African American Men: The Effect of Androgens and microRNAs on Epidermal Growth Factor Signaling

Development of Metabolic Syndrome Associated to Cancer Therapy: Review

Relation of Serum Estrogen Metabolites with Terminal Duct Lobular Unit Involution Among Women Undergoing Diagnostic Image-Guided Breast Biopsy

Synchronous vs. Metachronous Metastases in Adrenocortical Carcinoma: an Analysis of the Dutch Adrenal Network

Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie